On December 12, 2025, Telling Fred, a director at Oragenics Inc (NASDAQ: OGEN), divested 210 shares of the company’s common stock, generating proceeds close to $198. The shares were sold at an average price of $0.9446 per share, with the execution prices ranging narrowly between $0.9440 and $0.9451. This transaction took place while Oragenics shares were trading near $0.91, marking a significant depreciation of nearly 88% over the preceding 12 months.
Further adding to the recent insider activity, on December 11, 2025, the same director secured 125,000 Non-Employee Director Options. These options grant the right to purchase shares at an exercise price of $0.93 and were vested immediately upon acquisition. The options carry an expiry date slated for December 11, 2035, implying a potential long-term investment perspective.
Oragenics, classified as a micro-cap biotechnology enterprise, has encountered marked volatility in its share prices. Yet, financial analysis from InvestingPro highlights that the company maintains a robust balance sheet. With a current ratio of 4.42, the company appears capable of meeting its short-term liabilities comfortably. Likewise, its debt-to-capital ratio is minimal at 0.09, signifying limited leverage and comparatively low financial risk within the capital structure.
Despite the adverse stock performance evidenced over the last year, the company’s valuation metrics appear encouraging when measured against InvestingPro’s Fair Value estimate. This suggests that, from a valuation standpoint, Oragenics might currently be undervalued.
InvestingPro further identifies seven additional investment recommendations pertaining to Oragenics, which are accessible to subscribers, potentially offering further insights into the company’s financial and market outlook.
This analysis was generated utilizing artificial intelligence tools and subsequently reviewed by a human editor to ensure accuracy and clarity for investors and market participants.